Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
作者信息
Piccioni David E, Lai Albert
机构信息
Department of Neurosciences, UCSD Moores Cancer Center, La Jolla, California (D.E.P.); Neuro Oncology Program, David Geffen School of Medicine at UCLA., Los Angeles, California (A.L.).
出版信息
Neuro Oncol. 2014 Oct;16(10):1427-8. doi: 10.1093/neuonc/nou214. Epub 2014 Aug 25.
Abstract
摘要
相似文献
1
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.复发性胶质母细胞瘤延迟使用贝伐单抗并不影响疗效。
Neuro Oncol. 2014 Oct;16(10):1427-8. doi: 10.1093/neuonc/nou214. Epub 2014 Aug 25.
2
Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?贝伐单抗延迟用于胶质母细胞瘤是否与生存期延长相关？
Neuro Oncol. 2014 Oct;16(10):1427. doi: 10.1093/neuonc/nou150. Epub 2014 Jul 22.
3
Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined?贝伐单抗治疗胶质母细胞瘤：新的标准疗法已经确定了吗？
CNS Drugs. 2011 Oct 1;25(10):815-8. doi: 10.2165/11587880-000000000-00000.
4
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.推迟使用贝伐珠单抗治疗复发性脑胶质瘤并不降低疗效。
Neuro Oncol. 2014 Jun;16(6):815-22. doi: 10.1093/neuonc/nou028. Epub 2014 Mar 13.
5
Predicting glioblastoma response to bevacizumab through marker profiling?通过标志物分析预测胶质母细胞瘤对贝伐单抗的反应？
Neuro Oncol. 2016 Feb;18(2):149-50. doi: 10.1093/neuonc/nov320.
6
The role of avastin in the management of recurrent glioblastoma.阿瓦斯汀在复发性胶质母细胞瘤治疗中的作用。
Neurosurg Clin N Am. 2012 Apr;23(2):331-41, x. doi: 10.1016/j.nec.2012.02.001. Epub 2012 Feb 25.
7
Bevacizumab for glioblastoma: what can we learn from patterns of progression?贝伐单抗治疗胶质母细胞瘤：从进展模式中我们能学到什么？
Neurology. 2014 May 13;82(19):1670-1. doi: 10.1212/WNL.0000000000000421. Epub 2014 Apr 11.
8
Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.阿瓦斯汀治疗多形性胶质母细胞瘤的分子特征和途径。
Neurosurg Clin N Am. 2012 Jul;23(3):417-27. doi: 10.1016/j.nec.2012.05.002.
9
Outcome of discontinuing bevacizumab prior to malignant glioma progression.在恶性胶质瘤进展前停用贝伐单抗的结果。
J Neurooncol. 2013 Jan;111(1):87-9. doi: 10.1007/s11060-012-0985-2. Epub 2012 Oct 12.
10
Bevacizumab antiangiogenic therapy for glioblastoma.贝伐单抗用于胶质母细胞瘤的抗血管生成治疗。
Neurology. 2011 Feb 1;76(5):414-5. doi: 10.1212/WNL.0b013e31820a0d7e.
引用本文的文献
1
Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.复发性胶质母细胞瘤：初始复发及后续复发的治疗策略
Curr Treat Options Oncol. 2016 Sep;17(9):49. doi: 10.1007/s11864-016-0422-4.
2
Bevacizumab for glioblastoma.贝伐单抗治疗胶质母细胞瘤。
Ther Clin Risk Manag. 2015 Dec 1;11:1759-65. doi: 10.2147/TCRM.S58289. eCollection 2015.
3
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.卡铂和贝伐单抗治疗复发性胶质母细胞瘤的随机2期研究。
Neuro Oncol. 2015 Nov;17(11):1504-13. doi: 10.1093/neuonc/nov104. Epub 2015 Jun 30.
4
Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma.动脉自旋标记灌注磁共振成像可对胶质母细胞瘤的无进展生存期进行分层，并与表皮生长因子受体状态相关。
AJNR Am J Neuroradiol. 2015 Apr;36(4):672-7. doi: 10.3174/ajnr.A4196. Epub 2014 Dec 26.
本文引用的文献
1
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.复发性胶质母细胞瘤患者早期与延迟使用贝伐单抗治疗的生存结果。
J Neurooncol. 2014 Aug;119(1):135-40. doi: 10.1007/s11060-014-1460-z. Epub 2014 May 7.
2
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.贝伐珠单抗联合放疗-替莫唑胺治疗新诊断的胶质母细胞瘤。
N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.
3
A randomized trial of bevacizumab for newly diagnosed glioblastoma.贝伐珠单抗治疗新诊断的胶质母细胞瘤的随机试验。
N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.
Zotero 插件